LANZ (LANZ) Stock Price & Analysis
LANZ (LANZ) rose 0.00% to USD 0.04 as of June 10, 2026 at 11:50 UTC, according to Nexqual real-time market data.
LANZ last closed at USD 0.04; the session ranged USD 0–0 on volume of 8,072 shares. Market capitalization is $42.82M, with a 52-week range of USD 0–0.04 (PNK). Source: Nexqual, June 10, 2026 at 11:50 UTC.
Key Statistics (as of June 10, 2026 at 11:50 UTC)
| Price | USD 0.04 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.04 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.04 |
| Volume | 8,072 shares |
| Market Cap | $42.82M |
| Exchange | PNK |
Technical Analysis (LANZ)
Nexqual's technical model rates LANZ "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 11:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0.03) |
| MACD | 0 (positive) |
Analyst Ratings (LANZ)
Wall Street analysts rate LANZ "None", per Nexqual as of June 10, 2026 at 11:50 UTC.
| Consensus Rating | None |
|---|
Earnings (LANZ)
Source: Nexqual, June 10, 2026 at 11:50 UTC.
Financials & Fundamentals (LANZ)
| Total Revenue | $6.19M |
|---|---|
| Revenue Growth (YoY) | +12.30% |
| Gross Margin | +31.71% |
| Operating Margin | -5.49% |
| Profit Margin | +1.71% |
| ROE | +3.31% |
| Current Ratio | 4.53 |
| Total Cash | $126,905 |
| Total Debt | $0 |
| Free Cash Flow | $-569,821 |
Source: Nexqual, June 10, 2026 at 11:50 UTC.
Financial Health Score (LANZ)
Nexqual rates LANZ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:50 UTC.
| Growth | Solid — Revenue +12% YoY (latest Q) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $127K cash, no debt |
| Cash Flow | Weak — FCF negative: -$570K, burning cash |
| Efficiency | Weak — ROE 3%, ROA 0.5% |
Ownership (LANZ)
| Shares Outstanding | 0 |
|---|
Source: Nexqual, June 10, 2026 at 11:50 UTC.
Leadership (LANZ)
LANZ is led by Alejandro Abbiate, Vice President of International Sales & Marketing, per Nexqual as of June 10, 2026 at 11:50 UTC.
| Vice President of International Sales & Marketing | Alejandro Abbiate |
|---|---|
| Secretary and Director | Janet Moore (age 74) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADLI | AMERICAN MEDICAL TECHNOLOGIES | USD 0 | ▲ 0% |
| HMGN | HEMAGEN DIAGNOSTICS INC | USD 0 | ▲ 0% |
| HDII | Hypertension Diagnostics, Inc. | USD 0 | ▲ 0% |
| OMRX | ORTHOMETRIX INC | USD 0 | ▲ 0% |
| NIMU | Non-Invasive Monitoring Systems | USD 0.06 | ▼ 14.29% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:50 UTC. This page is informational and not investment advice.